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CC BY-NC-ND license (http://creativeAbstract The prevalence of diabetes and its complications is increasing at an alarming rate
in both developed and deve1oping nations. The emerging evidences highlighted that both ge-
netic and epigenetic mechanisms including histone modifications play a significant role in the
pathogenesis of diabetic nephropathy (DN). Histone deacetylases (HDACs) and acetylation are
involved in the regulation of autophagy as well as pathogenesis of DN. Both HDACs and histone
acetyltransferases (HATs) play a key role in chromatin remodeling and affect the transcription
of various genes involved in the cellular homeostasis, apoptosis, immunity and angiogenesis.
Further, HDAC inhibitors are exert the renoprotective effects in DN and other diabetic compli-
cations. Thus, the cellular acetylation plays a crucial role in the regulation of autophagy and
can be explored as a new therapeutic target for the treatment of DN. This review aimed to
delineate the role of HDACs and associated molecular signaling/pathways in the regulation
of autophagy with an emphasis on promising targets for the treatment of DN.
Copyright ª 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Diabetic nephropathy (DN), a micro-vascular complication,
which leads to end-stage renal disease (ESRD).1 DN is
characterized by the excessive deposition of extracellular2 2214683x2152; fax: þ91 172 22
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commons.org/licenses/by-nc-nd/matrix (ECM) with thickening of glomerular basement
membranes and mesangial expansion in both glomerular
and tubulo-interstitial compartments as well as persistent
micro-albuminuria.2,3 It is also associated with reduced
renal function, podocyte damage and proteinuria.14692.
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patients develop nephropathy, but evidences are higher in
type-1 diabetic patients and ultimately lead to ESRD.4,5 DN
has several distinct phases of development. The structural
and functional changes occur in the glomerulus and tubules
such as glomerular hyper-filtration, hyper-perfusion,
thickening of glomerular basement membrane and
glomerular hypertrophy as well as mesangial expansion.6,7
Excessive accumulation of ECM in glomerular mesangial
and tubulo-interstitial compartments as well as, epithelial-
to-mesenchymal transition (EMT) of renal tubular epithelial
cells are the hallmark of DN.8 In DN, the renal hemody-
namic changes involve the activation of various vaso-active
systems such as rennin-angiotensin-aldosterone systems
(RAAS), which results in the secretion of pro-fibrotic mol-
ecules such as transforming growth factor b1 (TGF-b1),
advanced glycosylated end-products (AGEs), activation
protein kinase C (PKC) and acceleration of the aldose
reductase pathway increases systemic and intra-glomerular
pressure, thereby hyper-perfusion, hyper-filtration and
other functional changes, which lead to leakage of proteins
from the glomerular capillaries.8,9 Further, DN is also
associated with podocytes damage; which are terminally
differentiated highly specialized epithelial cells. It plays an
important role in maintaining the integrity of glomerular
filtration barrier and acts as a critical size and charge
barrier to prevent proteinuria.10 Thus, DN is associated with
compromised renal function, podocyte damage and subse-
quent proteinuria, which ultimately lead to ESRD.
Several mechanisms such as oxidative stress, inflamma-
tion, genetic and epigenetic alterations as well as auto-
phagy are contributed in the pathogenesis of DN.11e13
However, the exact role of autophagy has not been stud-
ied in DN. Autophagy is a catabolic cellular process by
which cells degrade and recycle the dysfunctional proteins
and damaged organelles to maintain the cellular homeo-
stasis under stress conditions such as starvation, hypoxia,
endoplasmic reticulum (ER)-stress and hyperglycemia.14,15
Several reports highlighted that the dysfunctional proteins
and organelles are accumulated in DN due to reduce
autophagy.16,17 Further, deficiency of autophagy leads to
chronic kidney injury, which is associated with ischemia-
reperfusion, hypoxia and DN.18e20
Recent studies emphasized that the epigenetic mecha-
nisms like histone modifications (acetylation), DNA
methylation and microRNA play a significant role in the
development and progression of DN.21,22 Histone deacety-
lases (HDACs) are the enzymes, which remove the acetyl
group from lysine residues of histone proteins, while his-
tone acetyltransferases (HATs) add the acetyl group on the
histone and ultimately regulate the gene expression.23,24
HDACs are involved in several biochemical pathways and
contribute in the pathogenesis and progression of DN.25e27
HDAC1 has been found to trigger fibroblast activation,
proliferation and chemokine production in the interstitial
renal fibroblasts and tubular epithelial cells.22 Recently, it
has been reported that HDAC2/4/5 are up-regulated in both
experimental and clinical DN and play a critical role in its
progression by reducing autophagy.23,28 Moreover, podo-
cytes exposed to high glucose and transforming growth
factor-b1 (TGF-b1) increased the expression of HDAC4,
suggesting its contribution in DN.23,29 On the other hand,HDAC inhibitors possess the renoprotective and anti-fibrotic
activities against various pathophysiological insults in dia-
betes, which confirm that HDACs play a central role in
DN.21,30,31 Further, valproic acid showed renoprotective
effect in DN by decreasing the expression of HDAC4/5 and
improving autophagy through HDAC inhibition and histone
acetylation.32 The kidney of STZ-induced diabetic rats, db/
db mice and TGF-b1-treated NRK52-E cells showed marked
elevation of HDAC-2 activity, which increased the expres-
sion of fibronectin and SMA, while decreased the expression
of E-cadherin.33 Moreover, HDAC inhibitors also exert
beneficial effects in various nephrotic and non-nephrotic
pathological conditions through chromatin-dependent and
independent mechanisms.31,34e37 Considering the recent
literature, it is clearly evident that HDACs and autophagy
are the key contributors in the pathogenesis and progres-
sion of DN (Table 1). This review provides the novel insights
on the role of HDACs, cellular acetylation and the associ-
ated molecular signaling/pathways, which modulate the
autophagy and DN with an emphasis on promising thera-
peutic targets.Autophagy: an overview
Autophagy is a cellular catabolic process, which degrades
and recycles the unwanted proteins and organelles in cell
to maintain cellular homeostasis under stress and patho-
logical conditions.36,38,39 In the other words, autophagy
recycles the intracellular energy resources in response to
nutrient depletion, removes the cytotoxic proteins and
organelles under physiological conditions (Fig. 1).14,40 Every
cell has a unique feature to sense the nutrients availability
and produce a specific response via adenosine mono-
phosphate (AMP)-activated protein kinase (AMPK),
mammalian target of rapamycin (mTOR) and sirtuins (SIRTs)
mediated nutrient sensing pathways for the cellular
homeostasis.41e43 Apart from this, cellular energy level
regulates autophagy through the nutrient-sensing signaling
depending on cell requirement.19,44 Depletion of energy
level activates autophagy by the inhibition of mTOR or
activation of AMPK and SIRT1, to degrade the unnecessary
cellular components, thereby providing energy and other
substrate to the cell.43e46 The above pathways regulate the
efficient nutrient utilization by autophagy for the cell
growth and survival (Fig. 2). In general, these pathways are
directly and indirectly involved in the pathogenesis of dia-
betes, cancer and obesity. Further, nutrient regulatory
pathway modulates the post-translational modifications
including HDAC-mediated de-acetylation of various target
proteins of autophagy as well as many physiological
processes.45,47,48
The process of autophagy involves a series of dynamic
membrane rearrangements regulated by a set of ATG pro-
teins.49 This comprise of four protein complexes, which
constitute core molecular machinery i.e., the kinase com-
plex ATG1eATG13 (initiator), phosphatidylinositol-3 kinase
(PI3K) complex I (BECN1, ATG14, PIK3C3/VPS34 and PIK3R4/
VPS15) as well as two ubiquitin-like protein conjugation
complexes i.e, ATG12eATG5-ATG16L1 and LC3ePE.24,50 In
brief, the process of autophagy is accomplished in the
following steps.
Table 1 Role of HDACs and their inhibitors in the development, progression and treatment of DN.
S.No Mechanism/Inference involved Model/Species References
1 HDAC4 contributes in the podocyte injury associated
with compromise autophagy and exacerbates
inflammation by HDAC4-STAT1 signaling in DN.
Rat and clinical DN 23
2 Sodium valproate ameliorates diabetes-induced fibrosis,
proteinuria and renal damage by the inhibition of iNOS/
NF-kB signaling and activation of autophagy through
HDAC inhibition in diabetic rat.
Rat 13,32
3 MS-275 inhibits renal fibroblast activation via TGF-b1 and
EGFR signaling.
UUO-induced fibrosis in rat 28
4 Sodium butyrate decreases fibrosis, apoptosis and DNA
damage in kidney by HDAC inhibition.
Juvenile diabetic rat 11
5 HDAC inhibition by vorinostat attenuates diabetes-
associated kidney growth via reducing eNOS activity and
oxidative stress as well as epigenetic modification of
EGFR.
Proximal tubule cells culture
and diabetic animals
65,66,11
6 Valproic acid and class I selective HDAC inhibitor SK-7041
prevent TGF-b1-induced ECM accumulation and EMT by
the inhibition of HDAC2.
Rat and NRK52-E cells. 33
7 TSA prevents TGF-b1-induced apoptosis by inhibiting ERK
activation in human renal proximal tubular epithelial
cells.
In vitro 29
Note: Sirtuins (SIRTs), particularly SIRT1 activators are also exerted the renoprotective effects in DN, but not listed here, because its
activity is decreased in DN due to reduce level of NADþ, which is an essential co-factor for SIRTs activity.
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Figure 1 Schematic diagram showing the overview of basic and molecular processes involved in autophagy. The process of
autophagy involves a series of dynamic membrane rearrangements regulated by a set of ATG proteins, which can be modulated by
the post-translational modifications (re-review in ref. 52, 53 and 70). In brief, it involves the following key steps i) control of
phagophore formation by beclin-1/VPS34 at the ER and other membranes in response to stress such as starvation or diabetes; ii)
Atg5eAtg12 conjugation, interaction with Atg16L and polymerization at the immature phagophore; iii) the LC3 processing and
insertion into the extending phagophore membrane; iv) then engulfing of random or selective targets for degradation, completion
of the autophagosome and recycling of some LC3-II/ATG8 v) and finally fusion of the autophagosome with the lysosome and
proteolytic degradation by lysosomal proteases of engulfed molecules or cellular debris.
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Autophagy is triggered by Ulk1 (unc-51-like kinase), a
SereThr protein kinase/ATG1 mediated phosphorylation of
ATG13 and FIP 200 or RB1-inducible coiled-coil protein 1
(RB1CC1 or ATG 17), which are necessary for phagophore
formation.51Nucleation
Formation of the phagophore (pre-autophagosomal) by
beclin-1 complex, composed of beclin-1/ATG6, B-cell lym-
phoma 2 (BCL-2) family proteins and large macro-molecule
complex also known as class III PI3K vacuolar protein sorting
34 and ATG14 as well as Vps15.52
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Figure 2 Schematic diagram showing the influences on cell survival and death in diabetes. The metabolic changes in diabetes
induce various cellular stresses, which inhibit the regulation of protective mechanisms by nutrient/energy sensing pathways. The
equilibrium between the two opposing processes is altered during the progression of DN, which modulate the cell survival
pathways.
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Autophagosomal maturation involves two ubiquitin-like
conjugation systems; ATG12, which form the
ATG12eATG5eATG16 complex and microtubule-associated
protein light chain 3 (LC3/ATG8) system.53 The LC3-
phosphatidylethanolamine (PE)-conjugation occurs by a
pair of consecutive ubiquitination-like reactions catalyzed
by E1-like enzyme ATG7 and E2-like enzyme ATG3, which
forms LC3-phosphatidylethanolamine conjugate (LC3-
II).53,54 Thus, LC3-II formation is recognized as a marker
for the presence of autophagosomes in cell culture and
animal experiments.55,56Fusion and breakdown of contents
After formation the autophagosomes, it merges with the
lysosomal compartment to form autolysosomes for acid
hydrolase-mediated hydrolysis/degradation of cellular un-
wanted and toxic materials.53
Based on the mechanism and function, autophagy is
divided into three types; macroautophagy, microautophagy
and chaperone-mediated autophagy, which are controlled
by the evolutionarily conserved autophagy related genes
(ATG). The activity of core ATG, transcription factors and
cytoskeleton proteins are tightly regulated under normalphysiological condition to maintain the basal level of
autophagy.24,50
Role of autophagy in the progression and
treatment of DN
Several studies reported the compromised autophagy in DN,
obesity, aging and neurodegenerative disorders.20,57,58 The
kidney cells seem to be more susceptible to the metabolic
alterations due to high level of basal autophagy.15,19 Thus,
deficiency of autophagy might play a critical role in the
progression of diabetes-associated renal damages.15,59 In
diabetes, the altered nutrient levels (glucose and others)
triggered the specific response in the kidney cell and
modulated the post-translational modifications like acety-
lation of target proteins and ultimately autophagy.45,47 In
experimental models of type-1 and type-2 diabetes, the
expression and activity of SIRT1 have been reduced in the
kidney.60e62 In addition, SIRT1 plays essential role in
metabolic alterations and protects against the high-fat diet
(HFD)-induced insulin-resistance and hyperglycemia due to
decrease activity of the SIRT1.63 Moreover, selenium
nanoparticles and rhein reduced the oxidative stress and
renal injury in type-1 and type-2 diabetes-associated DN by
the increased action of SIRT1, respectively.46,61 Further,
accelerated renal fibrosis and apoptosis are observed in
unilateral ureteral obstruction (UUO) model due to
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energy balance of cell and/or acetylation of various pro-
teins, which ultimately modulates the autophagy, thereby
contributes in the DN.
Autophagy influences glomerular disease susceptibility
and also serves as an essential physiological process for the
maintenance of post-mitotic cells like podocyte.19 Deletion
of podocyte specific ATG5 leads to glomerulopathy and
proteinuria in aging mice due to limited capacity of
regeneration in the podocyte.15 Valproic acid, a HDAC in-
hibitor exerts reno-protective effects and prevents the
podocyte effacement by inactivation of iNOS/NF-kB
signaling as well as facilitates the autophagy through HDAC
inhibition.13,32 Another report highlighted that HDACs and
histone acetylation control the nitric oxide (NO) production
through eNOS/iNOS activity in DN and HDAC inhibition
ameliorated the TGF-b1-induced fibrogenesis, apoptosis
and DNA damage.11,65,66 It can be postulated that kidney
damage in diabetes might be triggered by hyperglycemia,
which subsequently leads to perturbations in autophagy
and associated signaling. Thus, it can be concluded that
autophagy is an important survival process, which, helps to
overcome stress-induced pathological perturbations and
might be a promising strategy for the prevention and
treatment of DN.Role of protein acetylation in autophagy
regulation and DN
Autophagy is regulated by the post-translational modifica-
tions of ATG proteins such as acetylation and phosphory-
lation in response to nutrients status or growth factor levels
as well as various stress and pathological conditions. Star-
vation activates the SIRT1, which deacetylates the ATG7,
ATG12, ATG5 and LC-3 (ATG8).19,67 Further, starvation also
facilitates the acetylation of ATG3 by KAT5, which regu-
lates its interaction with microtubule-associated proteins
1A/1B light chain 3B (LC3B) as well as lipidation of LC3B.24
Nutrients excess (diabetes) increase the HDACs activity and
reduce the acetylation of ATG3 and autophagy in skeletal
muscle homeostasis in mice.24,31 Forkhead box protein O
(FOXO), an evolutionarily conserved transcription factor,
regulates many biological processes like autophagy, cell
proliferation, cell death, DNA repair and metabolism.68,69
The acetylation status of FOXO1 and FOXO3 controls its
transcription activation and modulates the various genes
required for autophagosome formation.70,71 Moreover, the
de-acetylated FOXO also facilitates the expression of Ras-
related protein Rab-7 (RAB7), which is responsible for the
fusion of autophagosome and lysosome.24,69 Similarly,
HDAC6 regulates the autophagy by recruiting the actin and
tubulin networks as well as cortactin to ubiquitinated pro-
tein aggregates by de-acetylation.72 Thus, it can be
considered that HDAC6-mediated partial LC3B-II de-acety-
lation might be involved in autophagy during serum star-
vation.2 Additionally, it has also been reported that
acetylated microtubules are necessary for the fusion of
autophagosomes with lysosomes to form autolyso-
somes.24,69 In contrast, acetylation of ATG5, ATG7, ATG8
and ATG12 by p300, an acetyltransferase inhibits the pro-
cess of elongation and maturation of the autophagosomemembranes in in-vitro experiments.24,73 on the other hand,
different HDACs can deacetylate the lysine residue of his-
tone H3 (H3K56) and modulate the transcription of partic-
ular ATG genes, thereby autophagy.74,75 Considering the
current literature, it can be postulated that the protein
acetylation plays a critical role in the regulation of auto-
phagy. However, the overall role of protein acetylation on
autophagy is still controversial, because both acetylation
and de-acetylation of protein at specific targets can
modulate the process of autophagy.70,71
Recently, HDAC inhibition by VPA ameliorates the
podocyte and renal injuries by the activation of autophagy
and the inactivation of NF-kB/iNOS signaling in kidney of
diabetic rat.32 Further, HDAC4 deacetylates the STAT1,
which facilitates its phosphorylation and the subsequent
nuclear trans-location and ultimately leads to inflammation
and apoptosis as well as reduce the expression of ATGs
(autophagy).23,76 In contrast, it has been reported that the
acetylation of NF-kB (p65) and STAT3 are increased in both
mouse and human diabetic kidney with the progression of
DN due to decrease activity of SIRT1, most probably
because of reduced level of NADþ, which is an essential co-
factor for SIRTs activity.77 Moreover, a growing number of
non-histone proteins, such as p53, FOXO, NF-kB, STAT3 and
LC3II-B are identified as substrates of HDACs or SITRs and
de-acetylation of these proteins can modulate the auto-
phagy.78 On the other hand, TGF-b1 and other genes
expression including HDACs have been up-regulated during
the fibrogenesis and renal damage in diabetic kidney of
rats.13,48 However, it has been reported that exposure of
TGF-b1 to human renal proximal tubular epithelial cells up-
regulated the autophagy-related genes such as ATG5, ATG7
and beclin-1. Despite the critical role of acetylation/de-
acetylation in autophagy, the exact molecular signaling of
autophagy should be explored to answer how HDACs and
SIRTs suppress the autophagy in DN despite their opposite
level exist in diabetes.20,41,76 Taken together, HDACs with
other molecular signaling can compromise the autophagy
and significantly contributed in the development and pro-
gression of DN (Fig. 3). Further, there is urgent need to
investigate the exact role of different HDAC isoforms not
only in the regulation of autophagy, but also in the other
physiological conditions to understand their exact contri-
bution in physiology and development of DN (Table 2).
The process of de-acetylation differs markedly between
sirtuins (SIRTs) and HDACs. While class I, II, and IV HDACs
transfer the final acetyl group and are sensitive to the in-
hibitor trichostatin A (TSA), while sirtuins (SIRTs) require
NADþ as an enzymatic co-factor, transfer the acetyl group
from the substrate to an ADP-ribose molecule, and are
insensitive to TSA or other HDAC inhibitors. So the mecha-
nisms and activities as well as the de-acetylation by SIRTs
and HDACs are greatly modulated by the pathological
conditions, particularly in diabetes.79 Further, class I, II and
IV HDACs are up-regulated in DN (are pathogenic in nature)
and their inhibitors exert beneficial effects in diabetic pa-
tients and rodents. In contrast, SIRTs (III HDACs) are sup-
pressed in diabetes due to decreased NADþ level and
activation of SIRTs by resveratrol or calorie restriction
promotes energy metabolism, thereby exerts beneficial
effects in diabetes/DN.47,80 Additionally, both type of en-
zymes also have non-histone targets and directly or
 Diabetes/Hyperglycemia
HDACs Insulin/ IGF SIRTs
AMPK
p-Akt
TSC1
TSC2 Atg12-Atg5-Atg16L1 complex
LC3BI LC3BII
FOXO1
FOXO3
AUTOPHAGY
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4E-BP
S6K1
Hif1a
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Figure 3 Role of HDACs and associated pathways involved in the processes of autophagy during the progression of DN. High
glucose level under diabetic condition inhibits PI3K/AKT, AMPK and SIRT1 signaling as well as activates mTORC1 pathway, which
ultimately lead to the development and progression of DN. Reduced autophagy activates fibroblast, endothelial and podocyte
damage leading to fibrosis, apoptosis and DNA damage, which ultimately contributes in the progression of DN.
216 S. Khan et al.indirectly modulate the cellular acetylation status and
subsequently affect the activities of various autophagy
proteins.76,81 Thus, HDACs and SIRTs may regulate the
conformation, localization, molecular interaction, and
function of various autophagy proteins by controlling their
acetylation status.
Although, there is an opposite levels of SIRTs and HDACs
in DN, but overall, the global de-acetylation by the SIRTs
and HDACs in DN suppresses the autophagy through regu-
lation of the conformation, localization, molecular inter-
action and function of various target proteins and
transcription factors, which directly and/or indirectly pro-
mote the autophagy. However, de-acetylation on specific
molecules may have a very critical role on autophagy.
Therefore, targeting de-acetylation/acetylation on specific
target molecule will provide the exact role of SIRTs and
HDACs on the regulation of autophagy in DN. Further, both
type of enzymes have non-histone targets and directly or
indirectly modulate the cellular acetylation status and
subsequently affect the activities of various autophagy
proteins.24,80,82 Moreover, SIRTs (SIRT1) activators exert an
anti-apoptotic and pro-autophagic responses in cells under
stress conditions as well as diabetes by directly de-
acetylating essential ATGs such as ATG5, ATG7 and ATG8as well as by de-acetylation of various transcription factors
such as FOXO3 and ultimately increased the expression of
autophagy proteins.62 Similarly, HDAC inhibitors also pro-
mote the autophagy through transcriptional activation of
FOXO1 and up-regulating ATGs as well as suppression of
mTOR signaling by phosphorylation of AKT.20,71 Considering
the current literature, protein acetylation, an important
form of post-translation modification control by HATs and
HDACS, is involved in the regulation of autophagy. Intrigu-
ingly, it is still controversial how protein acetylation mod-
ulates autophagy. In diabetes, over expression of HDACs
may de-acetylated the histones and non-histone target
proteins at specific sites and modulate the molecular
signaling of autophagy, thereby ultimately suppress the
autophagy.23,62 In contrast, reduced activity of SIRTs can
acetylate the various proteins such as FOXO, NF-kB, STAT3,
p53 and LC3II-B, which directly or indirectly suppress
autophagy in DN. Therefore, acetylation/de-acetylation of
different autophagy proteins by HDACs and SIRTs, particu-
larly in DN might have very complex role in autophagy,
which cannot be explained in general. The future studies
will elucidate that how different HDACs or SIRTs and sub-
sequent protein acetylation are involved in autophagy and
eventually in DN.
Table 2 Role of different HDACs or SIRTs isoforms and protein acetylation status in the regulation of autophagy in DN.
HDAC classes HDAC isoforms Specific role and involvement in DN References
Class I HDAC 1 Did not contribute in DN as well as autophagy. 23
HDAC 2 Up-regulated and contributed in DN and may contribute in
autophagy.
23,33
HDAC 3 Did not contribute in DN as well as autophagy. 23
HDAC 8 Did not contribute in DN as well as autophagy. 23
Class IIa HDAC 4& 5 Up-regulated in DN and played a major role in the
pathogenesis of DN by the inhibition of autophagy.
23,32
HDAC 7 Up-regulated and contributed in the diabetic kidney
damages, but its effect on autophagy is still unexplored.
13
HDAC 9 Did not contribute in DN as well as autophagy. 23
Class IIb HDAC 6 Did not contribute in DN as well as autophagy. 23
HDAC 10 Did not contribute in DN as well as autophagy. 23
Class III (Sirtuins or SIRTs) SIRT1 Reduced activity and subsequently compromised the
autophagy in DN and aging. Reduced activity of SIRT1 can
acetylate the various proteins such as FOXO, NF-kB, STAT3,
p53 and LC3II-B, which directly or indirectly suppressed
autophagy in DN.
19,46,41
SIRT2-7 No report available on their role in the pathogenesis of DN
and autophagy so far.
e
Class IV HDAC 11 Did not contribute in DN as well as autophagy. 23
Note: The above reports presented here are summarizing the current status of HDACs and SIRTs and their contribution in DN and
autophagy. Since different isoform of HDACs and SIRTs are expressed in a tissue specific manner under physiological and pathological
conditions. Therefore, the role of different HDACs and SIRTs may vary in different pathological conditions, even in the different tissues
of the same pathological condition. Therefore, the acetylation/de-acetylation of different autophagic proteins by HDACs and SIRTs,
particularly in DN might play a very complex role in autophagy, which cannot be explained in general.
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Several molecular signaling are involved in the pathogen-
esis and progression of DN, which can be modulated by both
genetic and epigenetic mechanisms. The emerging evi-
dences highlighted that epigenetic mechanisms including
histone modifications play a critical role in the pathogen-
esis of DN. The altered cellular acetylation and subsequent
modulation of genes and transcription factors affect the
autophagy in DN. Modulation of acetylation status of ATG
proteins may be one of the best possible targets to promote
the autophagy and tissue repair to attenuate kidney dam-
age in DN. Thus, modulation of cellular acetylation by
multiple ways can emerge as a new therapeutic approach
for the prevention of DN. The different HDACs serve very
distinct physiological functions and currently available
HDAC inhibitors are mostly nonselective (pan-inhibitors) in
nature and inhibit multiple HDACs. In addition, the use of
pan-HDAC inhibitors might be associated with adverse side
effects due to unknown physiological functions.83,84
Therefore, it is very important to delineate the exact bio-
logical role of individual HDACs in the normal physiology
and pathological conditions, particularly in DN. Thus, tar-
geting the most relevant HDAC isoform in a particular
signaling during the progression of DN may greatly improve
the efficacy of novel HDAC inhibitors with minimal chance
of toxicities.
In conclusion, here we present the role of cellular
acetylation in the regulation of autophagy and its possible
usefulness for the treatment of DN. Thus, we conclude that
the regulation of autophagy could be an attractivetherapeutic strategy for the prevention and treatment of
DN. The detail understanding of the biological and patho-
logical roles of HDACs in tissue specific manner will provide
pinpoint targets for the DN, which can promote the
designing and synthesis of more selective inhibitors for
promising drug molecules for the treatment of DN. On the
other hand, advancement of the synthetic technology and
drug designing can allow the medicinal chemists to design
and synthesize more specific HDAC inhibitors, which can
provide a new dimension to drug discovery and develop-
ment for the treatment of DN.
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